Tweet
J Microbiol Immunol Infect
. 2022 Dec 21;S1684-1182(22)00284-5.
doi: 10.1016/j.jmii.2022.12.003. Online ahead of print.
Recommendations and guidelines for the diagnosis and management of Coronavirus Disease-19 (COVID-19) associated bacterial and fungal infections in Taiwan
Huan-Yi Wu 1 , Peng-Hao Chang 2 , Yu-Shan Huang 3 , Chin-Shiang Tsai 4 , Kuan-Yu Chen 5 , I-Fan Lin 6 , Wen-Hsin Hsih 7 , Wan-Lin Tsai 8 , Jiun-An Chen 9 , Te-Liang Yang 10 , Chun-Yuan Lee 11 , Tzong-Shiann Ho 12 , Hsiao-Wei Wang 13 , Shiang-Fen Huang 14 , Alice Ying-Jung Wu 15 , ****-Jui Chen 16 , Yi-Ching Chen 17 , Wan-Chen Chen 18 , Chien-Hao Tseng 19 , Pei-Chin Lin 20 , Ching-Hsiang Yang 21 , Pi-Lien Hong 21 , Susan Shin-Jung Lee 22 , Yao-Shen Chen 23 , Yung-Ching Liu 24 , Fu-Der Wang 25 ; Infectious Disease Society of Taiwan; Medical Foundation in Memory of Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education; CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccines,; 7th Guidelines Recommendations for Evidence-based Antimicrobial agents use in Taiwan (GREAT) working group; Members of the expert panel and board members of the IDST are listed in alphabetical order
Collaborators, Affiliations
- PMID: 36586743
- PMCID: PMC9767873
- DOI: 10.1016/j.jmii.2022.12.003
Abstract
Coronavirus disease-19 (COVID-19) is an emerging infectious disease caused by SARS-CoV-2 that has rapidly evolved into a pandemic to cause over 600 million infections and more than 6.6 million deaths up to Nov 25, 2022. COVID-19 carries a high mortality rate in severe cases. Co-infections and secondary infections with other micro-organisms, such as bacterial and fungus, further increases the mortality and complicates the diagnosis and management of COVID-19. The current guideline provides guidance to physicians for the management and treatment of patients with COVID-19 associated bacterial and fungal infections, including COVID-19 associated bacterial infections (CABI), pulmonary aspergillosis (CAPA), candidiasis (CAC) and mucormycosis (CAM). Recommendations were drafted by the 7th Guidelines Recommendations for Evidence-based Antimicrobial agents use Taiwan (GREAT) working group after review of the current evidence, using the grading of recommendations assessment, development, and evaluation (GRADE) methodology. A nationwide expert panel reviewed the recommendations in March 2022, and the guideline was endorsed by the Infectious Diseases Society of Taiwan (IDST). This guideline includes the epidemiology, diagnostic methods and treatment recommendations for COVID-19 associated infections. The aim of this guideline is to provide guidance to physicians who are involved in the medical care for patients with COVID-19 during the ongoing COVID-19 pandemic.
Keywords: CABI; CAC; CAM; CAPA; COVID-19; COVID-19 associated infections; Candidiasis; Mucormycosis; Pulmonary aspergillosis.